Ed on Sun Pharma

8/8/2019 Ed on Sun Pharma

http://slidepdf.com/reader/full/ed-on-sun-pharma 1/11

SunPharmaceuticals

Submitted to- Submitted By-

Dr. H. Sharma Yadavendra Singh



Its Established in 1983, Sun Pharma was a start-up companywith five products. Since 1996, Sun has grown largely through acombination of internal growth, and acquisition of otherpharmaceutical companies. For example, it bought US-basedCaraco Pharm Labs, and ICN Hungary.

Sun Pharmaceuticals is an international pharmaceuticalcompany based in Mumbai, India. It makes many generic andbrand name drugs that are distributed in the United States,Europe, Asia and worldwide.

As of 2008, it has grown to become an international specialitypharma company with more than 8000 employees, 19manufacturing locations worldwide, two research centres, and apresence in 30 countries. It is one of the leading Indian-basedpharma companies in India.



Sun Pharma's philosophy envisages workingtowards high levels of transparency,accountability, consistent value systems,

delegation across all facets of its operationsleading to sharply focused and operationallyefficient growth. The company tries to work bythese principles in all its interactions withstakeholders, including shareholders,employees, customers, suppliers and statutoryauthorities. Sun Pharma is committed to learnand adopt the best practices of corporategovernance.



Sun Pharma is highly regarded for its ability tolaunch new products with a great amount ofspeed and consistency.

The company has 20% exposure to the DPCO.

The past growth rate of the company hasalways been double that of the industry as awhole.



Continuous losses of Caraco Pharma is a majorconcern for Sun Pharma.

The profit margins are declining for thecompany



The relaxation of DPCO will be a big boost for thecompany and this might marginally improve theprofit margin.

Expanding the generic drugs market in USA

New venture in animal drugs

The company has entered the US market throughits subsidiary Caraco Pharma. This provides agreat opportunity for the company to make themost out of the expiring patents in USA



The entry of foreign players will pose a majorthreat to the company.

The company is more into acquisition basedgrowth and this might lead to a stage offinancial crunch as it has already happened in

the case of Caraco pharma. Sun pharmaprovided debt to Caraco and is facing problemsdue to the continuous losses made by the latter.



Create sustainable revenue streams

(i) Focus : Chronic therapies(ii) Differentiation : Technically complex products(iii) Speed to market

Seek cost leadership(i)Vertical integration : Development through

Manufacturingto Marketing

(ii) Optimise operational costs

Balance profitability and investments for future(i) Acquisitions yielding high ROI

(ii) Development of complex generics



It is a basically Public ltd. Organization and It·sa Decentralized Organization. And ItsPharmaceutical Industry.

Sun Pharmaceutical Industries Ltd acquired acontrolling stake in Israel·s TaroPharmaceutical Industries Ltd,



It have a strong ground network of 400 committed fieldforce in 30 countries, with a pipeline of over 2600products of which 1600 are registered and marketed.

We have 2500-person strong sales team inIndiadistributing through 2000 stockists.

In India, Its market over 500 products through 18speciality marketing divisions that are built aroundchronic therapy areas. Typically, every year Theyintroduce 25-30 new products.

Current global market size : USD 5.5 billion



Thank you

Ed on Sun Pharma

Documents

Transcript of Ed on Sun Pharma